Currently, according to researchers at Tufts University, patient dropout rates in clinical trials across various therapeutic areas are approaching 20%, and the consent process is the primary factor contributing to that number.
Furthermore, according to Adware“35% of patients who dropped out of the study early reported difficulty understanding the informed consent”.
Crucially, the consent process is tailored to ensure participants understand what they are being asked and how their data will help further future disease treatments.
Solution: Electronic Consent
Why?
1. eConsent simplifies overly lengthy and complex forms as it can be tailored to different audiences and has interactive, engaging elements.
2. Medable eConsent can recruit underrepresented and geographically diverse populations through remote consent, which has been shown to reduce screening timelines by 50%.
